$NRXS

$NRXS 1 year 248% YTD 81% 👇👇👇 ~$93M market cap, 33% revenue growth 84%+ gross margins Analyst targets up to $11. Risk/reward looks compelling. Business Model: NeurAxis commercializes IB-Stim a small wearable device using Percutaneous Electrical Nerve Field Stimulation (PENFS) to treat chronic abdominal pain in kids 🧑‍🧑‍🧒‍🧒via the gut-brain axis. Non-invasive, drug-free, sold B2B to pediatric GI clinics and hospitals. Only FDA-cleared device in its class with strong clinical evidence and growing insurance reimbursement. 💥 New RED device (diagnostic for anorectal disorders) adds a second revenue stream with EXISTING CPT code and broad coverage. Latest Financials (FY2025)📈 ✅ Revenue: $3.6M (+33% YoY) ✅ Gross Margin: 84% (best-in-class) ✅ Cash: $5M (runway ~8 mont